Enliven Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
OrbiMed Advisors and affiliated entities have reduced their beneficial ownership in Enliven Therapeutics, Inc. by more than 1%.
NASDAQ
OrbiMed Advisors filed an amendment to its Schedule 13D reporting a change in beneficial ownership of Enliven Therapeutics, Inc. common stock.
NASDAQ
OrbiMed Advisors and its affiliated entities have updated their Schedule 13D filing, reporting a reduced percentage ownership in Enliven Therapeutics, Inc. due to the company's recent public offering.